Down-regulation of transglutaminase II leads to impaired motility of cancer cells by inactivation of the protein kinase, Akt, and decrease of reactive oxygen species

Biotechnology Letters

Volumn 28, Issue 15, 2006, Pages 1151-1158

  Bae, Jinhee ^a   Lee, Yun Sil ^b   Jeoung, Dooil ^a  

^a Kangwon National University   (South Korea)

^b Korea Institute of Radiation and Medical Science   (South Korea)

Author keywords

Akt; Motility; Reactive oxygen species; Small interfering RNA; Transglutaminase II

Indexed keywords

MOTILITY; REACTIVE OXYGEN SPECIES; RNA INTERFERENCE; SMALL INTERFERING RNA; TRANSGLUTAMINASE II;

BIOCHEMISTRY; CELLS; OXYGEN; RNA; TUMORS; VACCINES;

ENZYMES;

CANCER VACCINE; GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; TRANSGLUTAMINASE 2;

ARTICLE; CELL ADHESION; CELL CULTURE; CELL MOTION; DOWN REGULATION; HELA CELL; HUMAN; LIVER TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL CULTURE;

CANCER VACCINES; CELL ADHESION; CELL MOVEMENT; DOWN-REGULATION; GTP-BINDING PROTEINS; HELA CELLS; HUMANS; LIVER NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING; TRANSGLUTAMINASES; TUMOR CELLS, CULTURED;

EID: 33746044867     PISSN: 01415492     EISSN: 15736776     Source Type: Journal    
DOI: 10.1007/s10529-006-9079-6     Document Type: Article

References (12)

1. Akimov SS, Belkin AM (2003) Opposing roles of Ras/Raf oncogenes and the MEK1/ERK signaling module in regulation of expression and adhesive function of surface transglutaminase. J Biol Chem 278:35,609-35,619
2. Bergamini CM, Signorini M, Barbato R, Menabo R, Di Lisa F, Gorza L, Beninati S (1995) Transglutaminase-catalyzed polymerization of troponin in vitro. Biochem Biophys Res Commun 206:201-206
3. Fabbi M, Marimpietri D, Martini S, Brancolini C, Amoresano A, Scaloni A, Bargellesi A, Cosulich E (1999) Tissue transglutaminase is a caspase substrate during apoptosis: cleavage causes loss of transamidating function and is a biochemical marker of caspase 3 activation. Cell Death Differ 6:992-1001
4. Gaudry CA, Verderio E, Jones RA, Smith C, Griffin M (1999) Tissue transglutaminase is an important player at the surface of human endothelial cells: evidence for its externalization and its colocalization with the beta (1) integrin. Exp Cell Res 252:104-113
5. Haroon ZA, Hettasch JM, Lai TS, Dewhirst MW, Greenberg CS (1999) Tissue transglutaminase is expressed, active, and directly involved in rat dermal wound healing and angiogenesis. FASEB J 79:1787-1795
6. Kang SK, Lee JY, Chung TW, Kim CH (2004) Overexpression of transglutaminase 2 accelerates the erythroid differentiation of human chronic myelogenous leukemia K562 cell line through PI3K/Akt signaling pathway. FEBS Lett 577:361-366
7. Lee ZW, Kwon SM, Kim SW, Yi SJ, Kim YM, Ha KS (2003) Activation of in situ tissue transglutaminase by intracellular reactive oxygen species. Biochem Biophys Res Commun 305:633-640
8. + T cell transendothelial migration. J Immunol 171:3179-3186
9. Oliverio S, Amendola A, Di Sano F, Farrace MG, Fesus L, Nemes Z, Piredda L, Spinedi A, Piacentini M (1997) Tissue transglutaminase-dependent posttranslational modification of the retinoblastoma gene product in promonocytic cells undergoing apoptosis. Mol Cell Biol 17:6040-6048
10. Stephens P, Grenard P, Aeschlimann P, Langley M, Blain E, Errington R, Kipling D, Thomas D, Aeschlimann D (2004) Crosslinking and G-protein functions of transglutaminase 2 contribute differentially to fibroblast wound healing responses. J Cell Sci 117:3389-3403
11. Takahashi H, Isobe T, Horibe S, Takagi J, Yokosaki Y, Sheppard D, Saito Y (2000) Tissue transglutaminase, coagulation factor XIII, and the pro-polypeptide of von Willebrand factor are all ligands for the integrins α 9β 1 and α 4β 1. J Biol Chem 275:23,589-23,595
12. Yuan L, Choi K, Khosla C, Zheng X, Higashikubo R, Chicoine MR, Rich KM (2005) Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas. Mol Cancer Ther 4:1293-1302